Rocuronium Bromide Main Life

Muscle relaxation as adjunct to anesth for tracheal intubation.

IV Adult Standard dose: 0.6 mg/kg. Maintenance dose: 0.1-0.2 mg/kg may be added during surgery as needed. In case of continuous infusion, initial rate should be 7 mcg/kg/min. Max dose: 0.9 mg/kg.

Patients w/ history of hypersensitivity to rocuronium Br or Br ion. Patients w/ severe myasthenia gravis & myasthenic syndrome, & those w/ history of hypersensitivity to sugammadex Na.

Administer w/ care to patients w/ dyspnea & airway obstruction, or bronchial asthma; patients w/ electrolyte abnormalities (eg, hypokalemia, hypocalcemia, hypermagnesemia), hypoproteinemia, dehydration, acidosis, hypercapnia; patients who use cardiopulmonary bypass by hypothermic anesth & hypothermic perfusion; patients w/ myasthenia gravis & myasthenic syndrome, or other neuromuscular disease (eg, muscular dystrophy, myotonic syndrome, congenital myopathy, spinal muscular atrophy, Guillain-Barré syndrome) or patients after polio disease; patients w/ reduced cardiac output; obese patients; burn patients; patients w/ liver, biliary or kidney disease; patients who are or may be pregnant; neonates, infants, toddlers or childn; elderly. Regulate breathing until adequate spontaneous breathing is restored. Use a muscle relaxation monitor as required to objectively evaluate the degree of muscle relaxation, & for safe & appropriate use of the drug. Caution in patients w/ history of anaphylactic reactions w/ suxamethonium Cl hydrate. Formation of sediments when mixed w/ amphotericin B, hydrocortisone succinate Na, methylprednisolone Na succinate, thiamylal Na, thiopental Na, or furosemide. Reports of prolonged muscle relaxation or quadriplegia over long-term continuous use for an unapproved indication of resp control. Avoid administration to lactating women.

Frequency unknown: Shock, anaphylaxis; prolonged resp depression; rhabdomyolysis; bronchospasm.

Muscle relaxation action may be reduced or potentiated depending on the sequence of co-administration w/ depolarizing muscle relaxants (eg, suxamethonium) or other non-depolarizing muscle relaxants. Potentiated muscle relaxation action w/ inhalation anaesth (eg, isoflurane, sevoflurane, halothane ether), lithium salt prep; K excretion type diuretic (eg, furosemide, thiazides); MAOI, protamines, β-blocker, metronidazole, Ca antagonist, cimetidine, bupivacaine; aminoglycosides, lincosamides, polypeptides, acylamino-penicillins, Mg salt prep, quinidine, quinine; IV administration of phenytoin during surgery; lidocaine. Reduced muscle relaxation action w/ CaCl₂ or KCl formulations; PI (eg, gabexate, ulinastatin); prolonged pre-administration of adrenocortical hormone agent, or antiepileptic agent (eg, carbamazepine, phenytoin). Accelerated onset of lidocaine action.

Neuromuscular Blocking Agents

M03AC09 - rocuronium bromide ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.

P₁S₁S₃